Anna Sjögren

Directeur Technique/Scientifique/R&D chez EGETIS THERAPEUTICS AB

56 ans

Health Technology

Consumer Services

Postes actifs de Anna Sjögren

Sociétés	Poste	Début	Fin
EGETIS THERAPEUTICS AB	Directeur Technique/Scientifique/R&D	-	-

Sociétés	Poste	Début	Fin
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Corporate Officer/Principal	01/01/2013	01/12/2017

University of Uppsala	Undergraduate Degree
Karolinska Institutet	Undergraduate Degree

Internationale

Suède

Opérationnelle

Undergraduate Degree	2
Chief Tech/Sci/R&D Officer	1
Corporate Officer/Principal	1

Sectorielle

Health Technology	3
Consumer Services	3

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
EGETIS THERAPEUTICS AB	Health Technology

Entreprise privées	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Entreprise privées

Health Technology